Oral GLP-1 Therapies Are Expected to Change the Obesity Treatment Landscape
Overview
A survey of 75 US physicians (primary care, endocrinology, and obesity specialists) highlights strong physician optimism around the role of oral GLP-1 therapies in transforming obesity management and expanding options for obesity treatment.
Awareness & Importance
- 80% report moderate to high familiarity
- 74% consider oral GLP-1 therapies highly important to the future of obesity treatment
Expected Benefits
- 80% anticipate increased patient access
- 72% expect better adherence vs injectables
- Greater patient acceptance due to oral dosing
- Earlier initiation of pharmacologic treatment
- Broader use in primary care settings for obesity management and use of GLP-1 for obesity
Prescribing Intent
78% of physicians say they are likely to prescribe oral GLP-1 therapies once available, and 80% expect them to play a frontline or major role in obesity treatment
Remaining Concerns
- Cost & reimbursement: 64%
- Long-term safety data: 56%
- Real-world effectiveness vs injectables: 50%
Outlook
Despite concerns, the outlook remains highly positive, with strong physician optimism and 78% of respondents expecting oral GLP-1 therapies and GLP-1 for obesity to meaningfully reshape the obesity management and obesity treatment landscape within the next five years.
Note: Percentages reflect the share of respondents selecting each response; some questions allowed multiple selections, so totals may exceed 100%.
